"Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company that develops diabetes, oncology, immunology and ...

The stock of Eli Lilly and Company LLY has declined 10.6% in a month ... Lilly’s revenue growth is being driven by higher ...

Verzenio and Taltz. The company operates in a single business segment: human pharmaceutical products. Eli Lilly has a deep pipeline in treatment areas focused on metabolic disorders, oncology ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 13 unusual trades. Delving into the details, we found 53% of ...

For Q3 2024, Aristotle Atlantic’s Large Cap Growth Composite posted a total return of 1.26% gross of fees, underperforming ...